UNASSIGNED: The literature on metastasis-directed therapy for oligometastatic @entity263 ( @entity263 ) recurrence consists of small heterogeneous studies. This study aimed to reduce the heterogeneity by pooling individual @entity1 data from different institutions treating oligometastatic @entity263 recurrence with stereotactic body radiotherapy (SBRT). We focussed on @entity1 who were treatment naive, with the aim of determining if SBRT could delay disease progression. We included @entity1 with three or fewer @entity3 . The Kaplan-Meier method was used to estimate distant progression-free survival (DPFS) and local progression-free survival (LPFS). @entity137 was scored using the Common Terminology Criteria for Adverse Events. In total, 163 @entity3 were treated in 119 @entity1 . The median DPFS was 21 mo (95% confidence interval, 15-26 mo). A lower radiotherapy dose predicted a higher local recurrence rate with a 3-yr LPFS of 79% for @entity1 treated with a biologically effective dose  <=100Gy versus 99% for @entity1 treated with >100Gy (p=0.01). Seventeen @entity1 (14%) developed @entity137 classified as grade 1, and three @entity1 (3%) developed grade 2 @entity137 . No grade >= 3 @entity137 occurred. These results should serve as a benchmark for future prospective trials. @entity1 SUMMARY: This multi-institutional study pools all of the available data on the use of stereotactic body radiotherapy for limited @entity263 @entity3 . We concluded that this approach is safe and associated with a prolonged treatment progression-free survival.

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic XXXX Treatment-naive Recurrence: A Multi-institutional Analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENT'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'PCa'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']
